Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Neuroendocrine Pathology of the Stomach: The Parma Contribution

(2014) Cesare Bordi   ENDOCRINE PATHOLOGY

A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (AZD0865) and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease

(2013) John Dent et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Is Proton Pump Inhibitor Therapy for Reflux Esophagitis Sufficient?: A Large Real-world Survey of Japanese Patients

(2013) Kazuhide Higuchi et al.   INTERNAL MEDICINE

Gastric carcinoids after long-term use of a proton pump inhibitor

(2012) C. S. Jianu et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)

(2012) Yasuyoshi Arikawa et al.   JOURNAL OF MEDICINAL CHEMISTRY

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands

(2011) Jun Matsukawa et al.   BIOCHEMICAL PHARMACOLOGY

A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals

(2011) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Safety of the long-term use of proton pump inhibitors

(2010) Alan BR Thomson   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials

(2009) S. J. EDWARDS et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Epidemiology and clinical characteristics of GERD in the Japanese population

(2009) Yasuhiro Fujiwara et al.   JOURNAL OF GASTROENTEROLOGY

Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population

(2009) Lars Agréus et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY